CDC20驱动雌激素受体阳性乳腺癌对CDK4/6抑制剂的获得性耐药

Purpose: Cyclin-dependent kinase (CDK) 4/6 inhibitors, such as palbociclib, in combination with endocrine therapy are the standard of care for patients with metastatic Estrogen Receptor-positive (ER+) breast cancer. Despite significant clinical benefit, acquired resistance to CDK4/6 inhibitors is nearly universal, and therapeutic strategies to overcome such resistance remain limited. To identify novel molecular mediators of resistance, we employed an unbiased integrative approach combining transcriptomic profiles with palbociclib sensitivity data to uncover molecular drivers of CDK4/6 inhibitor resistance. Methods: We integrated RNA sequencing data from over 45 breast cancer cell lines with half-maximal inhibitory concentration (IC₅₀) values for palbociclib. We performed correlation analyses and identified candidate genes whose expression was associated with palbociclib response. Top correlated gene was validated using western blotting in parental MCF-7 cells and multiple genetically engineered palbociclib-resistant derivatives. Functional relevance was assessed through siRNA-mediated knockdown and overexpression experiments. In vitro cell survival assays and in vivo xenograft studies using athymic nude mice were performed to determine the impact of CDC20 modulation on palbociclib response. Results: CDC20 expression showed a strong positive correlation with palbociclib IC₅₀ values across multiple breast cancer cell lines, suggesting a potential role in mediating palbociclib response. Consistently, we observed a marked upregulation of CDC20 in palbociclib-resistant MCF-7 and T-47D derivative cells compared to their parental counterparts. Functional studies further supported this association; silencing CDC20 expression in resistant cells significantly restored their sensitivity to palbociclib. Conversely, overexpression of CDC20 in both MCF-7 and T-47D cells was sufficient to confer resistance to palbociclib. In vitro cell survival assays showed significantly reduced sensitivity to palbociclib in CDC20-overexpressing cells compared to parental controls (p<0.001, two-tailed t-test). In vivo , palbociclib treatment (100 mg/kg by oral gavage, daily) was completely ineffective in inhibiting the growth of MCF-7-CDC20 xenografts (p>0.5 for palbociclib vs. vehicle, unpaired two-tailed t-test). Conclusion: Together, these findings identify CDC20 as a key functional mediator of palbociclib resistance and highlight its potential as a therapeutic target to overcome resistance to CDK4/6 inhibitors in ER-positive breast cancer.